{
  "prompt": {
    "guidelineId": "cg1127-neonatal-abstinence-scoring-pdf",
    "fieldsProcessed": [
      "humanFriendlyName",
      "organisation",
      "yearProduced",
      "summary"
    ],
    "enhancedFields": 4,
    "contentLength": 6543
  },
  "response": "{\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Neonatal Abstinence Syndrome Assessment and Management\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"The text does not explicitly mention the publishing organization or institution. However, based on the content and style, it is likely from a national health service or a professional medical body, but no specific name like NHS, NICE, WHO, or RCOG is provided in the given text. Since no specific organization name is identifiable, I cannot return one. If you have additional text or a title page that includes the publishing organization, please provide that for accurate identification\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Neonatal Abstinence Syndrome (NAS) Guideline** **Scope**: Applies to pediatric, neonatal, and midwifery staff caring for newborns at risk of NAS due to maternal substance use. **Key Recommendations**: - **Assessment**: Monitor for withdrawal symptoms using scoring tools. - **Antenatal Care**: Provide education, neonatal unit visits if needed, and Hepatitis B vaccination if indicated. Refer to social services. - **Perinatal Care**: Avoid pethidine/diamorphine for opiate-dependent mothers; do not give naloxone. - **Postnatal Care**: Keep mother and baby together. Observe for withdrawal; start scoring and pharmacological treatment if needed. - **Opiate withdrawal**: Start morphine (125 mcg/kg/day) and wean based on NAS scores. - **Non-opiate withdrawal**: Phenobarbitone for alcohol, chlorpromazine for benzodiazepines. - **Discharge Criteria**: Stable NAS scores, normal feeding/sleeping, no morphine dose changes for 36 hours. Ensure social support. - **Follow-up**: Provide parent education, document weaning schedules, and conduct discharge planning. **Substance-Specific Risks**: Includes risks like prematurity (amphetamines, nicotine), placental abruption (cocaine), and withdrawal symptoms (opiates, benzodiazepines). **Monitoring**: Audit antenatal tasks, NAS scoring, and discharge processes\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "endpoint": "enhanceGuidelineMetadata",
  "timestamp": "2025-06-18T21-48-30",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"guidelineId\": \"cg1127-neonatal-abstinence-scoring-pdf\",\n  \"fieldsProcessed\": [\n    \"humanFriendlyName\",\n    \"organisation\",\n    \"yearProduced\",\n    \"summary\"\n  ],\n  \"enhancedFields\": 4,\n  \"contentLength\": 6543\n}\n\nA: {\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Neonatal Abstinence Syndrome Assessment and Management\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"The text does not explicitly mention the publishing organization or institution. However, based on the content and style, it is likely from a national health service or a professional medical body, but no specific name like NHS, NICE, WHO, or RCOG is provided in the given text. Since no specific organization name is identifiable, I cannot return one. If you have additional text or a title page that includes the publishing organization, please provide that for accurate identification\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Neonatal Abstinence Syndrome (NAS) Guideline** **Scope**: Applies to pediatric, neonatal, and midwifery staff caring for newborns at risk of NAS due to maternal substance use. **Key Recommendations**: - **Assessment**: Monitor for withdrawal symptoms using scoring tools. - **Antenatal Care**: Provide education, neonatal unit visits if needed, and Hepatitis B vaccination if indicated. Refer to social services. - **Perinatal Care**: Avoid pethidine/diamorphine for opiate-dependent mothers; do not give naloxone. - **Postnatal Care**: Keep mother and baby together. Observe for withdrawal; start scoring and pharmacological treatment if needed. - **Opiate withdrawal**: Start morphine (125 mcg/kg/day) and wean based on NAS scores. - **Non-opiate withdrawal**: Phenobarbitone for alcohol, chlorpromazine for benzodiazepines. - **Discharge Criteria**: Stable NAS scores, normal feeding/sleeping, no morphine dose changes for 36 hours. Ensure social support. - **Follow-up**: Provide parent education, document weaning schedules, and conduct discharge planning. **Substance-Specific Risks**: Includes risks like prematurity (amphetamines, nicotine), placental abruption (cocaine), and withdrawal symptoms (opiates, benzodiazepines). **Monitoring**: Audit antenatal tasks, NAS scoring, and discharge processes\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": null
}